The recombinant DNA technology market is estimated to be valued at USD 172.94 Bn in 2024 and is expected to reach USD 327.63 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031.
To learn more about this report, request sample copy
The recombinant DNA technology market is expected to witness rapid growth during the forecast period owing to increasing investments in research and development activities by pharmaceutical and biotech companies. With rising demand for protein therapeutics and monoclonal antibodies, the demand for recombinant DNA technology is also rising. Continuous advancements in genetic engineering tools and genomic analysis are further expected to drive the market growth. Adoption of recombinant proteins in healthcare and increasing availability of recombinant vaccines and hormones are some key factors propelling the market growth.
Increasing Technological Advancements are Facilitating the Production of Novel Products
Tremendous advancements combined with a wide range of applications of recombinant DNA technology to treat life-threatening human diseases such as cancer, diabetes, and infectious diseases are expected to be the major factors augmenting the market growth. According to the Global Diabetes Community, in 2021, an estimated 537 million adults are suffering from diabetes worldwide, and the number is expected to escalate to 643 million by 2030. Moreover, in February 2021, according to the World Health Organization (WHO), an estimated 6.7 million deaths were directly caused by diabetes and 2.2 million deaths were attributable to hyperglycemia or high blood glucose levels. Advancements in recombinant technologies have facilitated the development of long-acting therapeutic proteins for drug development as well as introduced gene therapy, which is a novel molecular medicine, thus supporting the growth of the recombinant DNA technology market by creating a positive impact on the treatment of genetic diseases. Moreover, the novel gene-editing tool – Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), can be used to target the destruction of abnormal genes in human cells, and it has provided scientists a powerful way to make precise changes to DNA of microbes, plants, mice, dogs, and human cells.
The field of recombinant DNA technology has experienced significant growth in applications related to healthcare. Many complex and challenging diseases such as cancer, genetic disorders, and infectious diseases are now being addressed through recombinant DNA approaches. By allowing the large-scale production of important biomolecules like insulin, growth hormones, and coagulation factors, this technology has revolutionized the treatment of diabetes, growth deficiencies, and hemophilia. Scientists are also using it to develop novel vaccines, model gene functions, and interactions, conduct gene therapy clinical trials, and better understand the molecular basis of diseases. Going forward, as the technology becomes more advanced and efficient, it is likely to play an even greater role in developing personalized medicine and precision therapies. Many pharmaceutical and biotech companies have increased their R&D investments in this area in search of the next breakthrough treatment. Its ability to produce custom therapeutic proteins on demand position it at the forefront of advancing modern medicine over the coming decade.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients